ClinConnect ClinConnect Logo
Search / Trial NCT01757132

Post-Approval Study of the Implantable Miniature Telescope

Launched by VISIONCARE, INC. · Dec 20, 2012

Trial Information

Current as of July 24, 2025

Enrolling by invitation

Keywords

ClinConnect Summary

ECD sub-study. At investigative sites participating in the ECD Sub-Group study, corneal endothelial cell density will be measured by non-contact specular microscopy in a subgroup of 150 patients enrolled in the IMT-PAS-01 in the eye schedule for and implanted with the intraocular telescope at study entry, 3 months, 12, months, 24 months, 36 months, 48 months and 60 months.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • stable severe (BVDCA of 10/160 or poorer) to profound (BCDVA of 20/800 or better) vision impairment caused by bilateral central scotomas associated with end-stage age-related macular degeneration.
  • 65 years of age or older
  • retinal findings of geographic atrophy or disciform scar with foveal involvement
  • visually significant cataract
  • agree to undergo pre- and post-surgery training and assessment
  • achieve at least a 5-letter improvement with external telescope
  • have adequate peripheral vision in the eye not scheduled for surgery
  • Exclusion Criteria:
  • Stargardt's macular dystrophy
  • Anterior chamber depth \< 3.0mm
  • Presence of corneal guttate
  • Do not meet minimum age and endothelial cell density requirements
  • evidence of CNV or treatment of CNV within the past 6 months
  • cognitive impairment that would interfere with ability to understand and complete Acceptance of Risk and Informed Decision Agreement or prevent proper training/rehabilitation
  • previous intraocular or cornea surgery of any kind in operative eye, including any type of surgery for either refractive or therapeutic purposes or who have prior or expected ophthalmic related surgery within 30 days preceding intraocular telescope surgery
  • history of steroid-responsive rise in intraocular pressure, uncontrolled glaucoma, or preoperative IOP \>22 mm Hg while on maximum medication
  • known sensitivity to post-operative medications
  • history of eye rubbing or an ocular condition that predisposes eye rubbing
  • myopia \>6.0 D
  • hyperopia \>4.0D
  • axial length \<21mm
  • narrow angle, i.e., \<Schaffer grade 2
  • cornea stromal or endothelian dystrophies, including guttate
  • inflammatory ocular disease
  • zonular weakness/instability of crystalline lens, or pseudoexfoliation
  • diabetic retinopathy
  • untreated retinal tears
  • retinal vascular disease
  • optic nerve disease
  • history of retinal detachment
  • intraocular tumor
  • retinitis pigmentosa

About Visioncare, Inc.

VisionCare, Inc. is a pioneering medical device company dedicated to advancing the field of ophthalmology through innovative solutions for vision-related disorders. Specializing in the development of cutting-edge implantable devices, VisionCare focuses on enhancing patient outcomes and quality of life by addressing unmet clinical needs in vision correction and management. With a commitment to rigorous research and clinical trials, the company aims to establish new standards of care in the treatment of eye diseases, leveraging its expertise to drive meaningful advancements in the field.

Locations

Atlanta, Georgia, United States

Sarasota, Florida, United States

Mcallen, Texas, United States

Sacramento, California, United States

Chesterfield, Missouri, United States

New York, New York, United States

Phoenix, Arizona, United States

Eugene, Oregon, United States

Beverly Hills, California, United States

Chandler, Arizona, United States

Phoenix, Arizona, United States

Fullerton, California, United States

Loma Linda, California, United States

Parker, Colorado, United States

Pensacola, Florida, United States

Ann Arbor, Michigan, United States

Patients applied

0 patients applied

Trial Officials

Oliver D Schein, MD

Principal Investigator

Johns Hopkins University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials